U.S. Stock News

United Parcel Service (UPS) is accelerating its Network of the Future plan by closing up to 200 manual sorting facilities and targeting roughly 30,000 voluntary job reductions in order to build a more automated, lower cost delivery network. See our latest analysis for United Parcel Service. UPS shares are trading at US$114.42, with a 30-day share price return of 7.72% and a 90-day share price return of 19.71%. The 1-year total shareholder return is 2.5% and the 3-year total shareholder return...

In early March 2026, Amphenol Corporation filed an omnibus shelf registration for debt securities, including instruments issued by its Amphenol Technologies Holding GmbH subsidiary, providing flexibility to raise capital in the debt markets as needed. The filing coincides with stronger-than-expected fourth-quarter 2025 results and a positive outlook for 2026, highlighting how Amphenol is pairing earnings momentum with additional financing options to support its growth initiatives. Against...

Klaviyo (NYSE:KVYO) has authorized a $500 million share repurchase program. The company also announced a new partnership with Google focused on AI driven customer experiences. The collaboration aims to connect search, messaging, and advertising into a more unified marketing platform for brands. Klaviyo is making these moves with its stock trading at $18.21 and a value score of 5, alongside mixed recent performance, up 14.7% over the past week but down 18.0% over the past month. Returns are...

Madison Square Garden Sports (MSGS) has drawn fresh attention after its board unanimously approved exploring a spin off that would separate the New York Knicks and New York Rangers into two independent, publicly traded companies. See our latest analysis for Madison Square Garden Sports. That spin off announcement and the CFO transition come after a strong run in the share price, with Madison Square Garden Sports posting a 90 day share price return of 48.11% and a 1 year total shareholder...

Marex Group (MRX) has drawn fresh attention after recent share price moves, with the stock showing double digit returns over the month and past 3 months. This has prompted investors to reassess the diversified financial services platform. See our latest analysis for Marex Group. The recent rally sits on top of a broader upswing, with a 30 day share price return of 10.97% and year to date share price return of 15.47%. The 1 year total shareholder return of 23.13% points to building momentum as...

OpenText recently expanded its FY26 share repurchase program by US$200 million to US$500 million and approved buying back up to 24,906,456 shares for cancellation, while also selling its Vertica analytics database business to Rocket Software for US$150 million. Together, the larger buyback and Vertica divestiture highlight a shift toward returning more capital to shareholders while sharpening the company’s focus on core information management offerings. We’ll now examine how the expanded...

NeoGenomics (NEO) has drawn fresh attention after launching RaDaR ST, a circulating tumor DNA assay designed to detect molecular residual disease in blood using patient specific panels and advanced bioinformatics. See our latest analysis for NeoGenomics. Despite the RaDaR ST launch and recent earnings and guidance updates, NeoGenomics' 30 day share price return of 21.23% and year to date share price return of 19.22% both point to fading near term momentum. At the same time, the 5 year total...

RadNet (RDNT) closed out FY 2025 with Q4 revenue of US$547.7 million and basic EPS of roughly US$0.01 loss, while trailing twelve month figures show revenue at about US$2.0 billion and basic EPS of roughly US$0.25 loss. The company has seen quarterly revenue move from US$471.4 million in Q1 2025 to US$547.7 million in Q4 2025, with basic EPS swinging between a US$0.51 loss and US$0.19 profit over the same span. This sets up a story that focuses on how quickly margins can stabilize from...

Linde (LIN) is back in focus as the stock reacts to rising natural gas costs tied to Middle East tensions and the closure of the Strait of Hormuz, a key route for global energy supplies. See our latest analysis for Linde. Beyond the immediate reaction to energy cost concerns, Linde’s share price has shown strong momentum, with an 11.46% 30 day share price return and an 18.70% year to date share price return. Over a longer horizon, the 1 year total shareholder return of 11.67% and 5 year total...

Daqo New Energy Corp. recently reported its fourth-quarter and full-year 2025 results, showing polysilicon production of 42,181 MT in the quarter and 123,652 MT for the year, alongside full-year sales of US$665.42 million and a net loss of US$170.51 million, and issued 2026 production guidance of 140,000–170,000 MT. The sharp year-on-year reduction in net loss and the company’s plan to lift output in 2026 suggest operations are gradually stabilizing despite ongoing industry overcapacity...

Ulta Beauty (ULTA) is back in focus after recent analyst updates highlighted strong holiday sales, expanding store space, and new partnerships, along with rapid international growth and leadership changes that are drawing fresh investor attention. See our latest analysis for Ulta Beauty. Ulta Beauty’s share price has climbed steadily over recent months, with a 23.5% 90 day share price return and a 94.1% 1 year total shareholder return, suggesting momentum has built as investors react to...

EOG Resources (EOG) has drawn fresh attention after its recent share move, with the stock last closing at $128.65. That puts its recent performance and underlying fundamentals back in focus for investors. See our latest analysis for EOG Resources. The recent 1 day share price return of 3.68% extends a stronger run, with a 30 day share price return of 14.73% and a 5 year total shareholder return of 120.24%. This suggests momentum has been building over both shorter and longer periods. If this...

In late February 2026, Alnylam Pharmaceuticals highlighted strong momentum for its RNAi franchise, including positive Phase 3 data and a favorable Canadian reimbursement recommendation for AMVUTTRA in transthyretin-mediated amyloid cardiomyopathy, alongside an upcoming presentation at the TD Cowen Health Care Conference in Boston. Together with upbeat analyst commentary on AMVUTTRA’s rollout and Alnylam’s growth profile, these updates have sharpened investor focus on the company’s rare...

Phillips 66, ticker NYSE:PSX, is seeking approval to purchase Venezuelan heavy crude directly from state owned producer PDVSA. The proposed move would allow the refiner to source crude without intermediaries, potentially reshaping its supply chain and cost structure. This development comes as US refiners assess supply options in light of shifting geopolitical and regulatory conditions around Venezuelan oil. For investors watching NYSE:PSX, this sourcing shift sits alongside a share price of...

Celsius Holdings (CELH) just reported fourth quarter and full year 2025 results, showing strong revenue growth and a swing to quarterly profitability. The report was followed by a sharp share price pullback as investors locked in gains. See our latest analysis for Celsius Holdings. That profit taking drop of 8.13% on the 1 day share price return comes after a strong run, with a 90 day share price return of 20.62% and a 1 year total shareholder return of 92.01%. Momentum has cooled slightly,...

Wondering whether Qiagen is still good value at around US$48.83, or if the easy gains are behind it? This article walks through the numbers so you can judge the price tag with more confidence. The stock is up 28.2% over the past year and 2.7% year to date. However, the past 30 days have seen a 9.0% decline after a 2.9% gain in the last week, which may have shifted how the market is thinking about risk and opportunity. Recent news around Qiagen has focused on its position in pharmaceuticals...

Why BNY’s new preferred stock moves matter for common shareholders Bank of New York Mellon Corporation (BK) has launched a proposed public offering of Series M Noncumulative Perpetual Preferred Stock via depositary shares, alongside a completed US$500m variable rate preferred fixed income deal. For you as a common shareholder, these preferred moves sit alongside BNY’s push into blockchain settlement, tokenization and AI driven onboarding. Together, they raise questions about capital...

In late February 2026, Trupanion reported its full-year 2025 results, highlighting a return to profitability with net income of US$19.4 million and surpassing US$1.00 billion in annual subscription revenue driven by pricing aligned to rising veterinary costs and improved operating margins. The company also issued an optimistic 2026 outlook, projecting total revenue of about US$1.55–US$1.58 billion and targeting adjusted operating income growth of roughly 19%, while exploring lower-priced...

In recent days, escalating conflict involving Iran and effective disruption around the Strait of Hormuz have pushed global oil prices sharply higher, focusing attention on Exxon Mobil’s large upstream operations. At the same time, Exxon Mobil confirmed that director Jeffrey W. Ubben will not seek re-election at the May 2026 shareholder meeting, though his departure is described as unrelated to the company. These developments highlight how sudden geopolitical supply risks can reinforce the...

Spire (SR) has drawn fresh attention after terminating the certificate of designations for its 5.90% Series A Cumulative Redeemable Perpetual Preferred Stock, along with recent earnings and dividend updates in the natural gas utilities sector. See our latest analysis for Spire. That change to Spire’s capital structure comes as the share price trades at US$91.66, with a 30 day share price return of 8.49% and a 1 year total shareholder return of 22.45%. The 5 year total shareholder return of...

In late February 2026, Pfizer and Astellas reported that PADCEV plus Keytruda cut the risk of tumor recurrence, progression or death in cisplatin-eligible muscle-invasive bladder cancer patients versus standard chemotherapy, while Pfizer also secured full FDA approval for BRAFTOVI-based combination therapy in first-line BRAF V600E-mutant metastatic colorectal cancer. Together, these oncology advances strengthen Pfizer’s presence in high-need cancer settings and may help offset pressure from...

Range Resources (RRC) is back in focus after reporting 2025 results with record operational efficiencies, setting a new 2026 capital plan and production guidance, and lifting its quarterly dividend payout to shareholders. See our latest analysis for Range Resources. The recent earnings beat, operational records and dividend increase appear to be feeding into solid momentum, with a 7 day share price return of 8.6% and a year to date share price return of 18.6%, while the 5 year total...

Bio-Rad Laboratories (BIO) has been drawing attention after a mixed stretch for the share price, with gains over the past year but declines over the past 3 months and year to date. See our latest analysis for Bio-Rad Laboratories. Recent trading has been choppy, with a 4.23% 7 day share price return following a weaker 30 day share price return of a 4.80% decline. A 12.23% decline over 90 days points to fading momentum despite a 9.02% 1 year total shareholder return. If this mixed performance...

Event context and recent share performance Maximus (MMS) has come onto investors’ radar after a period of mixed share performance. The stock is down roughly 22% over the past month and about 15% over the past 3 months. See our latest analysis for Maximus. Against this recent slide, Maximus still has a 1 year total shareholder return of 16.64%. However, the 3 year and 5 year total shareholder returns of 6.02% and 6.59% declines suggest fading longer term momentum. If Maximus’ move has you...